MCM
RPRX icon

MAI Capital Management’s Royalty Pharma RPRX Stock Holding History

MAI Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670K Buy
11,941
+3,464
+41% +$180K ﹤0.01% 1158
2026
Q1 		$407K Buy
8,477
+7,378
+671% +$323K ﹤0.01% 1109
2025
Q4 		$42.5K Buy
1,099
+658
+149% +$25.1K ﹤0.01% 2109
2025
Q3 		$15.5K Buy
441
+47
+12% +$1.7K ﹤0.01% 2527
2025
Q2 		$14.2K Buy
394
+192
+95% +$6.36K ﹤0.01% 2537
2025
Q1 		$6.29K Sell
202
-6
-3% -$190 ﹤0.01% 2655
2024
Q4 		$5.29K Buy
+208
New +$5.51K ﹤0.01% 2751

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's RPRX Position: Q2 2026 in Review

MAI Capital Management increased its Royalty Pharma (RPRX) stake by 41% in Q2 2026, buying an estimated $180K and bringing the position to 11,941 shares worth $670K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

MAI Capital Management first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • MAI Capital Management held 11,941 shares of Royalty Pharma worth $670K as of Q2 2026.
  • MAI Capital Management bought 3,464 Royalty Pharma shares in Q2 2026, an estimated $180K.
  • Royalty Pharma made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1158 holding.
  • MAI Capital Management first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.